Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103684 | 0.83 | CYP26A1 (0.34) | CYP26A1MMP2MMP9MMP8MMP13 | |
| SCHEMBL106837 | 0.70 | CYP1A2 (0.37) | CYP1A2SMN1; SMN2KDM4ELMNACYP2D6 | |
| SCHEMBL28840515 | 0.69 | CYP26A1 (0.35) | CYP26A1 | |
| SCHEMBL29749105 | 0.69 | CYP26A1 (0.35) | CYP26A1 | |
| SCHEMBL28840517 | 0.69 | CYP26A1 (0.35) | CYP26A1 | |
| SCHEMBL22735759 | 0.68 | CYP26A1 (0.38) | SMN1; SMN2CYP26A1 | |
| SCHEMBL22736538 | 0.66 | POLB (0.38) | CYP1A2SMN1; SMN2KDM4ELMNACYP26A1 | |
| SCHEMBL4072987 | 0.66 | CYP1A2 (0.42) | CYP1A2SMN1; SMN2KDM4ELMNACYP2D6 | |
| SCHEMBL20425505 | 0.66 | CYP1A2 (0.42) | CYP1A2SMN1; SMN2KDM4ELMNACYP2D6 | |
| SCHEMBL3165179 | 0.65 | ALOX15 (0.35) | CYP1A2SMN1; SMN2KDM4ELMNACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183254-B1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2017-06-21 | — | — | EP | disclosed |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2014-06-26 | — | — | US | disclosed |
| US-8759522-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-06-24 | — | — | US | disclosed |
| US-8729268-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-05-20 | — | — | US | disclosed |
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | Mirati Therapeutics, Inc. | 2012-04-19 | — | — | US | disclosed |
| EP-2426108-A1 | Processes and intermediates for preparing fused heterocyclic kinase inhibitors | MethylGene Inc. (CA) | 2012-03-07 | — | — | EP | disclosed |
| EP-2332536-A1 | Inhibitors of protein tyrosine kinase activity | MethylGene Inc. (CA) | 2011-06-15 | — | — | EP | disclosed |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | OTSUKA PHARMACEUTICAL CO. LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2011-03-31 | — | — | US | disclosed |
| EP-2183254-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | MethylGene Inc. (CA) | 2010-05-12 | — | — | EP | disclosed |
| WO-2009026717-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC. (CA) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095234-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING FUSED HETEROCYCLIC KINASE INHIBITORS | MAP3K19, MAP3K9, MAP4K2 | CYP1A2 1122/4885SMN1; SMN2 3577/4885KDM4E 776/4885 |
| US-20140179632-A1 | METHODS OF INHIBITING PROTEIN TYROSINE KINASE ACTIVITY | PTK2B, PRKACA, DSTYK | CYP1A2 4816/4885SMN1; SMN2 3148/4885KDM4E 1640/4885 |
| US-20110077240-A1 | INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | ABL1, ERBB2, TYRO3 | CYP1A2 4187/4885SMN1; SMN2 4292/4885KDM4E 1254/4885 |
| US-20110098293-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ABL1, ERBB2, TYRO3 | CYP1A2 4187/4885SMN1; SMN2 4292/4885KDM4E 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.